Between 46% & 65% Of People Taking GLP-1 Medications Discontinued Them Within A Year

Among more than 125,000 adults with overweight or obesity who were using a dual-labeled glucagon-like peptide-1 receptor agonist (GLP-1 RA) for weight loss and/or type 2 diabetes (T2D), 64.8% of those without T2D and 46.5% of those with T2D stopped taking the medication within a year. Of those who discontinued the medications, 36.3% of those without T2D and 47.3% of those with T2D started using the medications again. Those who regained 1% of the weight had a higher likelihood of resuming use, at 2.8% of those without T2D and . . .